Article - 26/07/2019 New test assay leads to discovery of new influenza virus infection route Researchers from the University of Freiburg have recently discovered a completely new mechanism that influenza viruses use to infect cells. This discovery was partly made possible by a so-called emulsion coupling assay - an extremely sensitive, digital detection method developed by Actome GmbH in collaboration with scientists from the Freiburg University of Applied Sciences and Hahn-Schickard. The assay is used to count individual molecules and…https://www.gesundheitsindustrie-bw.de/en/article/news/alternativer-infektionsweg-fuer-grippeviren-durch-neues-testverfahren-entdeckt
Dossier - 09/09/2019 Artificial intelligence in medicine: assistance for human senses There is no way around it. Whether we like it or not, artificial intelligence (AI) has long been part of our lives, in traffic management, marketing campaigns or in the fields of medicine and life sciences. AI is omnipresent, often without us being aware of it. Baden-Württemberg is home to one of the largest AI research consortia in Europe and has recently become one of the European hotspots for this key technology.https://www.gesundheitsindustrie-bw.de/en/article/dossier/artificial-intelligence-medicine-assistance-human-senses
Article - 09/10/2019 Epigenomics from the Cyber Valley Cyber Valley Stuttgart-Tübingen is a European hotspot for artificial intelligence and home to many renowned experts and scientists. They are now joined by Gabriele Schweikert, who heads up the Computational Epigenomics research group in the Cyber Valley’s Division of Computational Biology. Schweikert is interested in exploring epigenetic mechanisms using machine learning methods.https://www.gesundheitsindustrie-bw.de/en/article/news/epigenomik-aus-dem-cyber-valley
Article - 01/07/2019 Microswimmers for guided drug delivery Medicines should act as quickly as possible and ideally only at the site of disease. However, this may be difficult when the medicines are taken up via the digestive tract or the blood system. Researchers at the Max Planck Institute for Intelligent Systems in Stuttgart have now developed a biohybrid microrobot consisting of red blood cells and bacteria that can be loaded with active ingredients.https://www.gesundheitsindustrie-bw.de/en/article/news/microswimmers-guided-drug-delivery
Overview The event has already taken place https://www.gesundheitsindustrie-bw.de/en/event/the-event-has-already-taken-place
Dossier - 06/12/2019 Microbiome: human health is closely connected with our microbial communities People have 1.3 times more microorganisms than body cells. This microbial community influences how we digest our food, how active our immune system is, as well as whether we tend to be more anxious or curious. A number of diseases have also been shown to be associated with a disturbed microbiome. Researchers still have a long way to go before the knowledge acquired can be used for developing therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/microbiome-human-health-closely-connected-with-microbial-communities
Article - 18/11/2019 Researchers successfully rejuvenate the immune system in animal models It is well known that stem cells age. Even the human immune system loses its power with age. Since all immune cells are derived from blood-forming stem cells, it is quite natural to associate the weakening of the immune system (immune senescence) with the ageing of blood-forming stem cells. Stem cell researchers and immunologists from the University of Ulm have now demonstrated the important role that blood-forming cells play in the ageing of the…https://www.gesundheitsindustrie-bw.de/en/article/news/Researchers-successfully-rejuvenate-the-immune-system-in-animal-models
Article - 20/01/2020 Brain tumour patients could benefit from heavy ion therapy Glioblastoma is a malignant brain tumour. It does not respond anywhere near as well to conventional forms of therapy than other tumours because it contains particularly resistant cancer cells. Scientists at the Heidelberg Ion Beam Therapy Center (HIT) at Heidelberg University Hospital and the German Cancer Research Center have shown that heavy ion therapy is effective against these cells.https://www.gesundheitsindustrie-bw.de/en/article/news/Brain-tumour-patients-could-benefit-from-heavy-ion-therapy
Article - 04/02/2020 Medicine from the blue blood of marine snails A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails
Article - 08/11/2019 Nanorobots as future minimally invasive tools for the eye It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.https://www.gesundheitsindustrie-bw.de/en/article/news/Nanorobots-future-minimally-invasive-tools-for-eye
Expert interview on NTDs – part 3 - 24/09/2019 Neglected tropical diseases – Franz-Werner Haas: the role of technology and pharmaceutical companies Neglected tropical diseases (NTDs) are poverty-related infectious diseases that suffer from scant attention in terms of research or control. NTDs exist in the shadow of the "big three": malaria, tuberculosis and HIV/AIDS. They affect many people living in poverty in the emerging and developing countries of the tropics and subtropics. Active control can only be achieved when people with NTDs are treated effectively and given information…https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-franz-werner-haas-die-rolle-von-technologie-und-pharmaunternehmen
Article - 15/10/2019 docdirekt – a smart way to contact a doctor in Baden-Württemberg You feel unwell, but the family doctor’s practice is closed or it’s impossible to get an appointment at short notice. As part of their docdirekt project, the Baden-Württemberg Association of Statutory Health Insurance Physicians (in German: "Kassenärztliche Bundesvereinigung Baden-Württemberg (KVBW)) is now offering help for such cases. Everyone signed up to the statutory health insurance scheme will now be able to ring, contact via apps or…https://www.gesundheitsindustrie-bw.de/en/article/news/docdirekt-smart-zum-arzt-baden-wuerttemberg
Article - 22/10/2019 Using CAR T cells for treating cancer After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.https://www.gesundheitsindustrie-bw.de/en/article/news/using-car-t-cells-for-treating-cancer
Article - 30/09/2019 Do gut bacteria have something to do with autism? Autistic people have different gut microorganisms than non-autistic people. Researchers believe that a disturbed intestinal flora may play a role in developmental disorders of the brain such as autism. The emerging new field of metaproteomics could shed light onto the matter. A team led by Prof. Dr. Boris Macek from Tübingen has investigated the bacterial protein pool in the faeces of mice that display autistic behaviour.https://www.gesundheitsindustrie-bw.de/en/article/news/do-gut-bacteria-have-something-to-do-with-autism
Vision Zero in oncology - 02/09/2019 Call for a comprehensive master plan for preventing and treating cancer While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
Prime Vector Technologies GmbH - 09/04/2020 A modular brick system for developing a COVID-19 vaccine Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
Trenzyme GmbH - 20/05/2020 The SARS-CoV spike protein and its receptor The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.https://www.gesundheitsindustrie-bw.de/en/article/news/the-sars-cov-spike-protein-and-its-receptor
Review article (new edition) - 08/07/2020 Immunology – at the forefront of medical progress Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
Innovations in the field of endoscopy - 08/06/2020 Gastroscopies with pill cameras A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.https://www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille
Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Waiting for a SARS-CoV-2 vaccine Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
Multiple sclerosis - 12/03/2020 Direct application of biopharmaceuticals through the nose into the brain There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.https://www.gesundheitsindustrie-bw.de/en/article/news/Direct-application-of-biopharmaceuticals-through-the-nose-into-the-brain